{
  "file_name": "10.1007_s12032-025-02609-4.pdf",
  "n_pages": 42,
  "extracted_at": "2025-10-09T12:37:26.091952+00:00Z",
  "text": "Skip to main content\nAdvertisement\n[image]\n[image]\nLog in\nMenu\nFind a journal Publish with us Track your research\nSearch\n Cart\n1. Home \n2. Medical Oncology \n3. Article\nRecent advancements in\nnanoparticles for cancer\ntreatment\n•  Review Article\n•  Published: 10 February 2025\n•  Volume 42, article number 72, (2025)\n\n•  Cite this article\n[image] Medical Oncology Aims and scope \n Submit manuscript \n•  Dinesh Kumar Sharma\n1 \n•  \n804 Accesses\n•  \n9 Citations\n•  Explore all metrics \nAbstract\nNanotechnology is a significant factor that has assisted researchers in\novercoming medications’ permeability and retention effects. This article\ndiscusses how different nanoparticles, such as metallic nanoparticles,\ncarbon nanotubes (CNTs), and extracellular vesicles (EVs), are\ntransforming cancer treatments and diagnosis. While CNTs provide\nphotothermal qualities that enable synergistic effects when paired with\nchemotherapy, EVs provide biocompatibility and immune evasion,\nenabling effective drug transport. Because of their special optical and\nmagnetic characteristics, metallic nanoparticles are essential for imaging\nand targeted medication administration. When compared to traditional\ntreatments, these nanoparticles improve bioavailability, decrease\nsystemic toxicity, and increase therapeutic efficacy. Despite increased\ninvestigations, the number of licensed nano-drugs has remained\nrelatively high. More investigation is required into targeted drug delivery\n\nusing nanocarriers to minimize the shielding impact of the protein\ncorona, increase permeability and retention effects, and reduce toxicity\nto improve clinical translation. This study focuses on novel approaches\nand state-of-the-art cancer therapies using nanoparticles that target\ndifferent cancer cells. It also emphasized the advantages of nanoparticle-\nbased cancer therapies over conventional ones, their difficulties, and\nfuture promises.\nGraphical abstract\n[image]\n This is a preview of subscription content, log in via an institution \nto check access.\nAccess this article\nLog in via an institution \nSubscribe and save\n Springer+\nfrom €37.37 /Month\n•  Starting from 10 chapters or articles per month\n•  Access and download chapters and articles from more than 300k\nbooks and 2,500 journals\n•  Cancel anytime\n\nView plans \nBuy Now\nBuy article PDF 39,95 €\nPrice includes VAT (Indonesia)\nInstant access to the full article PDF.\nInstitutional subscriptions \nFig. 1\n[image]\nFig. 2\n[image]\nFig. 3\n[image]\nSimilar content being viewed by others\n[image]\nNanomaterials for cancer therapy: current progress and\nperspectives\nArticle Open access 31 May 2021\n[image]\nEnhancing the therapeutic efficacy of nanoparticles for\n\ncancer treatment using versatile targeted strategies\nArticle Open access 12 September 2022\n[image]\nCancer Nanotechnology for Drug Targeting and Delivery\nApproaches\nChapter © 2021\n Discover the latest articles, books and news in related subjects,\nsuggested using machine learning.\nExplore related subjects\n•  Cancer Nanotechnology\n•  Cancer Therapy\n•  Nanomedicine and Nanotoxicology\n•  Nanoparticles\n•  Oncology\n•  Cell-nanoparticle Interaction\nAvailability of data and material\nNo datasets were generated or analyzed during the current study.\nReferences\n\n1. Shukla E, Kara DD, Katikala T, et al. Self-nanoemulsifying drug\ndelivery systems (SNEDDS) of anti-cancer drugs: a multifaceted\nnanoplatform for the enhancement of oral bioavailability. Drug Dev\nInd Pharm. 2023;49(1):1–6. https://\ndoi.org/10.1080/03639045.2023.2182124.\nArticle  PubMed  CAS  Google Scholar \n2. Agnihotri TG, Gomte SS, Jain A. Emerging theranostics to combat\ncancer: a perspective on metal-based nanomaterials. Drug Dev\nInd Pharm. 2022;48(11):585–601. https://\ndoi.org/10.1080/03639045.2022.2153862.\nArticle  PubMed  CAS  Google Scholar \n3. Yao Y, Zhou Y, Liu L, et al. Nanoparticle-based drug delivery in\ncancer therapy and its role in overcoming drug resistance. Front\nMol Biosci. 2020;7:193. https://doi.org/10.3389/fmolb.2020.00193.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n4. Cheng Z, Li M, Dey R, et al. Nanomaterials for cancer therapy:\ncurrent progress and perspectives. J Hematol Oncol. 2021;14:1–\n27. https://doi.org/10.1186/s13045-021-01096-0.\nArticle  Google Scholar \n5. Dadwal A, Baldi A, Kumar NR. Nanoparticles as carriers for drug\ndelivery in cancer. Artif Cells, Nanomed Biotechnol.\n2018;46(sup2):295–305. https://\n\ndoi.org/10.1080/21691401.2018.1457039.\nArticle  PubMed  CAS  Google Scholar \n6. Palazzolo S, Bayda S, Hadla M, et al. The clinical translation of\norganic nanomaterials for cancer therapy: a focus on polymeric\nnanoparticles, micelles, liposomes and exosomes. Curr Med\nChem. 2018;25(34):4224–68. https://\ndoi.org/10.2174/0929867324666170830113755.\nArticle  PubMed  CAS  Google Scholar \n7. Chen Y, Gao DY, Huang L. In vivo delivery of miRNAs for cancer\ntherapy: challenges and strategies. Adv Drug Deliv Rev.\n2015;81:128–41. https://doi.org/10.1016/j.addr.2014.05.009.\nArticle  PubMed  CAS  Google Scholar \n8. Kalyane D, Raval N, Maheshwari R, et al. Employment of\nenhanced permeability and retention effect (EPR): Nanoparticle-\nbased precision tools for targeting of therapeutic and diagnostic\nagent in cancer. Mater Sci Eng C. 2019;98:1252–76. https://\ndoi.org/10.1016/j.msec.2019.01.066.\nArticle  CAS  Google Scholar \n9. Riley RS, Day ES. Gold nanoparticle-mediated photothermal\ntherapy: applications and opportunities for multimodal cancer\ntreatment. WIREs Nanomed Nanobiotechnol. 2017;9(4): e1449.\nhttps://doi.org/10.1002/wnan.1449.\n\nArticle  CAS  Google Scholar \n10. Ventola CL. Progress in nanomedicine: approved and\ninvestigational nanodrugs. Pharm Therapeut. 2017;42(12):742.\nGoogle Scholar \n11. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan\nWC. Analysis of nanoparticle delivery to tumours. Nat Rev Mater.\n2016;1(5):1–2. https://doi.org/10.1038/natrevmats.2016.14.\nArticle  CAS  Google Scholar \n12. Sindhwani S, Syed AM, Ngai J, et al. The entry of nanoparticles\ninto solid tumours. Nat Mater. 2020;19(5):566–75. https://\ndoi.org/10.1038/s41563-019-0566-2.\nArticle  PubMed  CAS  Google Scholar \n13. Far BF, Maleki-Baladi R, Fathi-Karkan S, et al. Biomedical\napplications of cerium vanadate nanoparticles: a review. J Mater\nChem B. 2024. https://doi.org/10.1039/D3TB01786A.\nArticle  Google Scholar \n14. Fathi-karkan S, Zeeshan M, Qindeel M, et al. NPs loaded with\nzoledronic acid as an advanced tool for cancer therapy. J Drug\nDeliv Sci Technol. 2023. https://doi.org/10.1016/\nj.jddst.2023.104805.\nArticle  Google Scholar \n\n15. Wu PH, Opadele AE, Onodera Y, et al. Targeting integrins in\ncancer nanomedicine: applications in cancer diagnosis and\ntherapy. Cancers. 2019;11(11):1783. https://doi.org/10.3390/\ncancers11111783.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n16. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for\ndrug delivery. Nat Mater. 2013;12(11):991–1003. https://\ndoi.org/10.1038/nmat3776.\nArticle  PubMed  CAS  Google Scholar \n17. Sohail A, Ahmad Z, Bég OA, et al. A review on hyperthermia via\nnanoparticle-mediated therapy. Bull Cancer. 2017;104(5):452–61.\nhttps://doi.org/10.1016/j.bulcan.2017.02.003.\nArticle  PubMed  Google Scholar \n18. Greish K. Enhanced permeability and retention (EPR) effect for\nanticancer nanomedicine drug targeting. Cancer Nanotechnol\nMethods Protocols. 2010. https://\ndoi.org/10.1007/978-1-60761-609-2_3.\nArticle  Google Scholar \n19. Bakhshi S, Shoari A, Alibolandi P, et al. Emerging innovations in\nvincristine-encapsulated nanoparticles: pioneering a new era in\noncological therapeutics. J Drug Deliv Sci Technol. 2024;91:\n105270. https://doi.org/10.1016/j.jddst.2023.105270.\n\nArticle  CAS  Google Scholar \n20. Zhang YN, Poon W, Tavares AJ, et al. Nanoparticle–liver\ninteractions: cellular uptake and hepatobiliary elimination. J Control\nRelease. 2016;240:332–48. https://doi.org/10.1016/\nj.jconrel.2016.01.020.\nArticle  PubMed  CAS  Google Scholar \n21. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex\ntissues that interface with the entire organism. Dev Cell.\n2010;18(6):884–901. https://doi.org/10.1016/j.devcel.2010.05.012.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n22. Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact\nof passive and active targeting in the era of modern cancer\nbiology. Adv Drug Deliv Rev. 2014;66:2–5. https://doi.org/10.1016/\nj.addr.2013.11.009.\nArticle  PubMed  CAS  Google Scholar \n23. Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of\nactive targeting nanoparticle delivery system for chemotherapeutic\ndrugs and traditional/herbal medicines in cancer therapy: a\nsystematic review. Int J Nanomed. 2018;4:3921–35. https://\ndoi.org/10.2147/IJN.S165210.\nArticle  Google Scholar \n\n24. Wang Y, Dossey AM, Froude JW 2nd, et al. PSA\nfluoroimmunoassays using anti-PSA ScFv and quantum-dot\nconjugates. Nanomedicine. 2008;3(4):475–83. https://\ndoi.org/10.2217/17435889.3.4.475.\nArticle  PubMed  CAS  Google Scholar \n25. Nowak C, K. Cheung J, M. Dellatore S, et al. Forced degradation\nof recombinant monoclonal antibodies: A practical guide. InMAbs\n2017;9(8):1217–1230. Taylor & Francis. https://\ndoi.org/10.1080/19420862.2017.1368602\n26. Zhang L, Zhai BZ, Wu YJ, et al. Recent progress in the\ndevelopment of nanomaterials targeting multiple cancer metabolic\npathways: a review of mechanistic approaches for cancer\ntreatment. Drug Deliv. 2023;30(1):1–8. https://\ndoi.org/10.1080/10717544.2022.2144541.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n27. Baig N, Kammakakam I, Falath W. Nanomaterials: a review of\nsynthesis methods, properties, recent progress, and challenges.\nMater Adv. 2021;2(6):1821–71. https://doi.org/10.1039/\nD0MA00807A.\nArticle  Google Scholar \n28. Nitheesh Y, Pradhan R, Hejmady S, et al. Surface engineered\nnanocarriers for the management of breast cancer. Mater Sci Eng\nC. 2021;130: 112441. https://doi.org/10.1016/j.msec.2021.112441.\n\nArticle  CAS  Google Scholar \n29. Pourmadadi M, Gerami SE, Ajalli N, et al. Novel pH-responsive\nhybrid hydrogels for controlled delivery of curcumin: overcoming\nconventional constraints and enhancing cytotoxicity in MCF-7\ncells. Hybrid Adv. 2024;6: 100210. https://doi.org/10.1016/\nj.hybadv.2024.100210.\nArticle  Google Scholar \n30. Masood F. Polymeric nanoparticles for targeted drug delivery\nsystem for cancer therapy. Mater Sci Eng C. 2016;60:569–78.\nhttps://doi.org/10.1016/j.msec.2015.11.067.\nArticle  CAS  Google Scholar \n31. Vijayan V, Reddy KR, Sakthivel S, et al. Optimization and\ncharaterization of repaglinide biodegradable polymeric\nnanoparticle loaded transdermal patchs: In vitro and in vivo\nstudies. Colloids Surf B: Biointerfaces. 2013;111:150–5. https://\ndoi.org/10.1016/j.colsurfb.2013.05.020.\nArticle  PubMed  CAS  Google Scholar \n32. Sharma DK, Pattnaik G, Behera A. Recent developments in\nnanoparticles for the treatment of diabetes. J Drug Target.\n2023;31(9):908–19. https://\ndoi.org/10.1080/1061186X.2023.2261077.\nArticle  PubMed  CAS  Google Scholar \n\n33. Martín-Saldaña S, Palao-Suay R, Aguilar MR, et al. Polymeric\nnanoparticles loaded with dexamethasone or α-tocopheryl\nsuccinate to prevent cisplatin-induced ototoxicity. Acta Biomater.\n2017;53:199–210. https://doi.org/10.1016/j.actbio.2017.02.019.\nArticle  PubMed  CAS  Google Scholar \n34. Gavas S, Quazi S, Karpiński TM. Nanoparticles for cancer therapy:\ncurrent progress and challenges. Nanoscale Res Lett.\n2021;16(1):173. https://doi.org/10.1186/s11671-021-03628-6.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n35. Bukhari SN. Emerging nanotherapeutic approaches to overcome\ndrug resistance in cancers with update on clinical trials.\nPharmaceutics. 2022;14(4):866. https://doi.org/10.3390/\npharmaceutics14040866.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n36. Rink JS, Plebanek MP, Tripathy S, et al. Update on current and\npotential nanoparticle cancer therapies. Curr Opin Oncol.\n2013;25(6):646–51. https://doi.org/10.1097/\nCCO.0000000000000012.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n37. Xiao X, Teng F, Shi C, et al. Polymeric nanoparticles—Promising\ncarriers for cancer therapy. Front Bioeng Biotechnol.\n2022;10:1024143. https://doi.org/10.3389/fbioe.2022.1024143.\n\nArticle  PubMed  PubMed Central  Google Scholar \n38. Martínez-Carmona M, Lozano D, Colilla M, et al. Lectin-conjugated\npH-responsive mesoporous silica nanoparticles for targeted bone\ncancer treatment. Acta Biomater. 2018;65:393–404. https://\ndoi.org/10.1016/j.actbio.2017.11.007.\nArticle  PubMed  CAS  Google Scholar \n39. Abedin MR, Powers K, Aiardo R, et al. Antibody–drug nanoparticle\ninduces synergistic treatment efficacies in HER2 positive breast\ncancer cells. Sci Rep. 2021;11(1):7347. https://doi.org/10.1038/\ns41598-021-86762-6.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n40. György B, Szabó TG, Pásztói M, et al. Membrane vesicles, current\nstate-of-the-art: emerging role of extracellular vesicles. Cell Mol\nLife Sci. 2011;68:2667–88. https://doi.org/10.1007/\ns00018-011-0689-3.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n41. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes,\nmicrovesicles, and friends. J Cell Biol. 2013;200(4):373–83. https://\ndoi.org/10.1083/jcb.201211138.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n42. Wei W, Ao Q, Wang X, et al. Mesenchymal stem cell-derived\n\nexosomes: a promising biological tool in nanomedicine. Front\nPharmacol. 2021;11: 590470. https://doi.org/10.3389/\nfphar.2020.590470.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n43. Thomas A, Teicher BA, Hassan R. Antibody–drug conjugates for\ncancer therapy. Lancet Oncol. 2016;17(6):e254–62. https://\ndoi.org/10.1016/S1470-2045(16)30030-4.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n44. Nieto C, Vega MA, Martin del Valle EM. Trastuzumab: more than a\nguide in HER2-positive cancer nanomedicine. Nanomaterials.\n2020;10(9):1674. https://doi.org/10.3390/nano10091674.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n45. Xu P, Wang R, Yang W, et al. A DM1-doped porous gold\nnanoshell system for NIR accelerated redox-responsive release\nand triple modal imaging guided photothermal synergistic\nchemotherapy. J Nanobiotechnol. 2021;19:1–9. https://\ndoi.org/10.1186/s12951-021-00824-5.\nArticle  CAS  Google Scholar \n46. Fu Q, Wang J, Liu H. Chemo-immune synergetic therapy of\nesophageal carcinoma: trastuzumab modified, cisplatin and\nfluorouracil co-delivered lipid–polymer hybrid nanoparticles. Drug\nDeliv. 2020;27(1):1535–43. https://\n\ndoi.org/10.1080/10717544.2020.1837294.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n47. Carvalho MR, Reis RL, Oliveira JM. Dendrimer nanoparticles for\ncolorectal cancer applications. J Mater Chem B. 2020;8(6):1128–\n38. https://doi.org/10.1039/C9TB02289A.\nArticle  PubMed  CAS  Google Scholar \n48. Lim J, Kostiainen M, Maly J, et al. Synthesis of large dendrimers\nwith the dimensions of small viruses. J Am Chem Soc.\n2013;135(12):4660–3. https://doi.org/10.1021/ja400432e.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n49. Lo ST, Kumar A, Hsieh JT, et al. Dendrimer nanoscaffolds for\npotential theranostics of prostate cancer with a focus on\nradiochemistry. Mol Pharm. 2013;10(3):793–812. https://\ndoi.org/10.1021/mp3005325.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n50. Li D, Fan Y, Shen M, et al. Design of dual drug-loaded dendrimer/\ncarbon dot nanohybrids for fluorescence imaging and enhanced\nchemotherapy of cancer cells. J Mater Chem B. 2019;7(2):277–85.\nhttps://doi.org/10.1039/C8TB02723D.\nArticle  PubMed  CAS  Google Scholar \n51. Pishavar E, Ramezani M, Hashemi M. Co-delivery of doxorubicin\n\nand TRAIL plasmid by modified PAMAM dendrimer in colon cancer\ncells, in vitro and in vivo evaluation. Drug Dev Indl Pharm.\n2019;45(12):1931–9. https://\ndoi.org/10.1080/03639045.2019.1680995.\nArticle  CAS  Google Scholar \n52. Tarach P, Janaszewska A. Recent advances in preclinical\nresearch using PAMAM dendrimers for cancer gene therapy. Int J\nMol Sci. 2021;22(6):2912. https://doi.org/10.3390/ijms22062912.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n53. Jędrzak A, Grześkowiak BF, Coy E, et al. Dendrimer based\ntheranostic nanostructures for combined chemo-and photothermal\ntherapy of liver cancer cells in vitro. Colloids Surf B: Biointerfaces.\n2019;173:698–708. https://doi.org/10.1016/j.colsurfb.2018.10.045.\nArticle  PubMed  CAS  Google Scholar \n54. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an\nupdate review. Curr Drug Deliv. 2007;4(4):297–305. https://\ndoi.org/10.2174/156720107782151269.\nArticle  PubMed  CAS  Google Scholar \n55. Visht S, Awasthi R, Rai R, et al. Development of dehydration-\nrehydration liposomal system using film hydration technique\nfollowed by sonication. Curr Drug Deliv. 2014;11(6):763–70.\nhttps://doi.org/10.2174/1567201811666140910122945.\n\nArticle  PubMed  CAS  Google Scholar \n56. Allen TM, Cullis PR. Liposomal drug delivery systems: from\nconcept to clinical applications. Adv Drug Deliv Rev.\n2013;65(1):36–48. https://doi.org/10.1016/j.addr.2012.09.037.\nArticle  PubMed  CAS  Google Scholar \n57. Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine:\ntherapeutic applications and developments. Clin Pharmacol Ther.\n2008;83(5):761–9. https://doi.org/10.1038/sj.clpt.6100400.\nArticle  PubMed  CAS  Google Scholar \n58. Wang X, Liu X, Li Y, et al. Sensitivity to antitubulin\nchemotherapeutics is potentiated by a photoactivable\nnanoliposome. Biomaterials. 2017;141:50–62. https://\ndoi.org/10.1016/j.biomaterials.2017.06.034.\nArticle  PubMed  CAS  Google Scholar \n59. Hofheinz RD, Gnad-Vogt SU, Beyer U, et al. Liposomal\nencapsulated anti-cancer drugs. Anticancer Drugs.\n2005;16(7):691–707. https://\ndoi.org/10.1097/01.cad.0000167902.53039.5a.\nArticle  PubMed  CAS  Google Scholar \n60. Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in\nvarious administration routes and future perspectives. Int J\n\nNanomed. 2007;2(3):289–300. https://doi.org/10.2147/\nIJN.S2.3.289.\nArticle  Google Scholar \n61. Lu B, Xiong SB, Yang H, et al. Solid lipid nanoparticles of\nmitoxantrone for local injection against breast cancer and its lymph\nnode metastases. Eur J Pharm Sci. 2006;28(1–2):86–95. https://\ndoi.org/10.1016/j.ejps.2006.01.001.\nArticle  PubMed  CAS  Google Scholar \n62. Das S, Chaudhury A. Recent advances in lipid nanoparticle\nformulations with solid matrix for oral drug delivery. AAPS\nPharmSciTech. 2011;12:62–76. https://doi.org/10.1208/\ns12249-010-9563-0.\nArticle  PubMed  CAS  Google Scholar \n63. Scioli Montoto S, Muraca G, Ruiz ME. Solid lipid nanoparticles for\ndrug delivery: pharmacological and biopharmaceutical aspects.\nFront Mol Biosci. 2020;7: 587997. https://doi.org/10.3389/\nfmolb.2020.587997.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n64. Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced\nmode of drug delivery system. 3 Biotech. 2015;5:123–7. https://\ndoi.org/10.1007/s13205-014-0214-0.\n\nArticle  PubMed  Google Scholar \n65. Gorain B, Choudhury H, Nair AB, et al. Theranostic application of\nnanoemulsions in chemotherapy. Drug Discov Today.\n2020;25(7):1174–88. https://doi.org/10.1016/j.drudis.2020.04.013.\nArticle  PubMed  CAS  Google Scholar \n66. Du M, Yang Z, Lu W, et al. Design and development of spirulina\npolysaccharide-loaded nanoemulsions with improved the antitumor\neffects of paclitaxel. J Microencapsul. 2020;37(6):403–12. https://\ndoi.org/10.1080/02652048.2020.1767224.\nArticle  PubMed  CAS  Google Scholar \n67. Dianzani C, Monge C, Miglio G, et al. Nanoemulsions as delivery\nsystems for poly-chemotherapy aiming at melanoma treatment.\nCancers. 2020;12(5):1198. https://doi.org/10.3390/\ncancers12051198.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n68. Ribeiro EB, de Marchi PG, Honorio-França AC, et al. Interferon-\ngamma carrying nanoemulsion with immunomodulatory and anti-\ntumor activities. J Biomed Mater Res A. 2020;108(2):234–45.\nhttps://doi.org/10.1002/jbm.a.36808.\nArticle  PubMed  CAS  Google Scholar \n69. Meng L, Xia X, Yang Y, et al. Co-encapsulation of paclitaxel and\n\nbaicalein in nanoemulsions to overcome multidrug resistance via\noxidative stress augmentation and P-glycoprotein inhibition. Int J\nPharm. 2016;513(1–2):8–16. https://doi.org/10.1016/\nj.ijpharm.2016.09.001.\nArticle  PubMed  CAS  Google Scholar \n70. Sánchez-López E, Guerra M, Dias-Ferreira J, et al. Current\napplications of nanoemulsions in cancer therapeutics.\nNanomaterials. 2019;9(6):821. https://doi.org/10.3390/\nnano9060821.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n71. Shakeel F, Ramadan W. Transdermal delivery of anticancer drug\ncaffeine from water-in-oil nanoemulsions. Colloids Surf B:\nBiointerfaces. 2010;75(1):356–62. https://doi.org/10.1016/\nj.colsurfb.2009.09.010.\nArticle  PubMed  CAS  Google Scholar \n72. Hou X, Sheng JJ. Properties, preparation, stability of\nnanoemulsions, their improving oil recovery mechanisms, and\nchallenges for oil field applications—a critical review. Geoenergy\nSci Eng. 2023;221: 211360. https://doi.org/10.1016/\nj.geoen.2022.211360.\nArticle  CAS  Google Scholar \n73. Swaminathan S, Pastero L, Serpe L, et al. Cyclodextrin-based\n\nnanosponges encapsulating camptothecin: physicochemical\ncharacterization, stability and cytotoxicity. Eur J Pharm Biopharm.\n2010;74(2):193–201. https://doi.org/10.1016/j.ejpb.2009.11.003.\nArticle  PubMed  CAS  Google Scholar \n74. Krishna KV, Ménard-Moyon C, Verma S, et al. Graphene-based\nnanomaterials for nanobiotechnology and biomedical applications.\nNanomedicine. 2013;8(10):1669–88. https://doi.org/10.2217/\nnnm.13.140.\nArticle  PubMed  CAS  Google Scholar \n75. Liu J, Dong J, Zhang T, et al. Graphene-based nanomaterials and\ntheir potentials in advanced drug delivery and cancer therapy. J\nControl Rel. 2018;286:64–73. https://doi.org/10.1016/\nj.jconrel.2018.07.034.\nArticle  CAS  Google Scholar \n76. Tao Y, Zhu L, Zhao Y, et al. Nano-graphene oxide-manganese\ndioxide nanocomposites for overcoming tumor hypoxia and\nenhancing cancer radioisotope therapy. Nanoscale.\n2018;10(11):5114–23. https://doi.org/10.1039/C7NR08747K.\nArticle  PubMed  CAS  Google Scholar \n77. Fiorillo M, Verre AF, Iliut M, et al. Graphene oxide selectively\ntargets cancer stem cells, across multiple tumor types: implications\nfor non-toxic cancer treatment, via “differentiation-based nano-\n\ntherapy.” Oncotarget. 2015;6(6):3553. https://doi.org/10.18632/\noncotarget.3348.\nArticle  PubMed  PubMed Central  Google Scholar \n78. Chen Z, Mao R, Liu Y. Fullerenes for cancer diagnosis and\ntherapy: preparation, biological and clinical perspectives. Curr\nDrug Metab. 2012;13(8):1035–45. https://\ndoi.org/10.2174/138920012802850128.\nArticle  PubMed  CAS  Google Scholar \n79. Bharadwaj A, Gupta M, Shakya A. A critical review on\nnanotechnology: a technique in cancer detection and prophylaxis.\nNano Life. 2023;13(03):2330004. https://doi.org/10.1142/\nS1793984423300042.\nArticle  CAS  Google Scholar \n80. Mroz P, Tegos GP, Gali H, et al. Photodynamic therapy with\nfullerenes. Photochem Photobiol Sci. 2007;6(11):1139–49. https://\ndoi.org/10.1039/b711141j.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n81. Ozgen PS, Atasoy S, Kurt BZ, et al. Glycopolymer decorated\nmultiwalled carbon nanotubes for dual targeted breast cancer\ntherapy. J Mater Chem B. 2020;8(15):3123–37. https://\ndoi.org/10.1039/C9TB02711D.\n\nArticle  Google Scholar \n82. Al Garalleh H, Algarni A. Modelling of paclitaxel conjugated with\ncarbon nanotubes as an antitumor agent for cancer therapy. J\nBiomed Nanotechnol. 2020;16(2):224–34. https://doi.org/10.1166/\njbn.2020.2886.\nArticle  PubMed  CAS  Google Scholar \n83. Karousis N, Suarez-Martinez I, Ewels CP, et al. Structure,\nproperties, functionalization, and applications of carbon\nnanohorns. Chem Rev. 2016;116(8):4850–83. https://\ndoi.org/10.1021/acs.chemrev.5b00611.\nArticle  PubMed  CAS  Google Scholar \n84. Yang J, Su H, Sun W, et al. Dual chemodrug-loaded single-walled\ncarbon nanohorns for multimodal imaging-guided chemo-\nphotothermal therapy of tumors and lung metastases.\nTheranostics. 2018;8(7):1966. https://doi.org/10.7150/thno.23848.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n85. Lucío MI, Opri R, Pinto M, et al. Targeted killing of prostate cancer\ncells using antibody–drug conjugated carbon nanohorns. J Mater\nChem B. 2017;5(44):8821–32. https://doi.org/10.1039/\nC7TB02464A.\nArticle  PubMed  Google Scholar \n\n86. Dubertret B, Skourides P, Norris DJ, et al. In vivo imaging of\nquantum dots encapsulated in phospholipid micelles. Science.\n2002;298(5599):1759–62. https://doi.org/10.1126/\nscience.1077194.\nArticle  PubMed  CAS  Google Scholar \n87. Gao X, Cui Y, Levenson RM, et al. In vivo cancer targeting and\nimaging with semiconductor quantum dots. Nat Biotechnol.\n2004;22(8):969–76. https://doi.org/10.1038/nbt994.\nArticle  PubMed  CAS  Google Scholar \n88. Pooresmaeil M, Namazi H, Salehi R. Synthesis of\nphotoluminescent glycodendrimer with terminal β-cyclodextrin\nmolecules as a biocompatible pH-sensitive carrier for doxorubicin\ndelivery. Carbohydr Polym. 2020;246: 116658. https://\ndoi.org/10.1016/j.carbpol.2020.116658.\nArticle  PubMed  CAS  Google Scholar \n89. Liu H, Li C, Qian Y, et al. Magnetic-induced graphene quantum\ndots for imaging-guided photothermal therapy in the second near-\ninfrared window. Biomaterials. 2020;232: 119700. https://\ndoi.org/10.1016/j.biomaterials.2019.119700.\nArticle  PubMed  CAS  Google Scholar \n90. Li X, Vinothini K, Ramesh T, et al. Combined photodynamic-\nchemotherapy investigation of cancer cells using carbon quantum\n\ndot-based drug carrier system. Drug Deliv. 2020;27(1):791–804.\nhttps://doi.org/10.1080/10717544.2020.1765431.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n91. Liu J, Li R, Yang B. Carbon dots: a new type of carbon-based\nnanomaterial with wide applications. ACS Cent Sci.\n2020;6(12):2179–95. https://doi.org/10.1021/acscentsci.0c01306.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n92. Jamieson T, Bakhshi R, Petrova D, et al. Biological applications of\nquantum dots. Biomaterials. 2007;28(31):4717–32. https://\ndoi.org/10.1016/j.biomaterials.2007.07.014.\nArticle  PubMed  CAS  Google Scholar \n93. Todaria M, Maity D, Awasthi R. Biogenic metallic nanoparticles as\ngame-changers in targeted cancer therapy: recent innovations and\nprospects. Future J Pharm Sci. 2024;10(1):25. https://\ndoi.org/10.1186/s43094-024-00601-9.\nArticle  Google Scholar \n94. Bagalkot V, Zhang L, Levy-Nissenbaum E, et al. Quantum dot−\naptamer conjugates for synchronous cancer imaging, therapy, and\nsensing of drug delivery based on bi-fluorescence resonance\nenergy transfer. Nano Lett. 2007;7(10):3065–70. https://\ndoi.org/10.1021/nl071546n.\n\nArticle  PubMed  CAS  Google Scholar \n95. Xu ZP, Zeng QH, Lu GQ, et al. Inorganic nanoparticles as carriers\nfor efficient cellular delivery. Chem Eng Sci. 2006;61(3):1027–40.\nhttps://doi.org/10.1016/j.ces.2005.06.019.\nArticle  CAS  Google Scholar \n96. Hlaváček A, Farka Z, Mickert MJ, et al. Bioconjugates of photon-\nupconversion nanoparticles for cancer biomarker detection and\nimaging. Nat Protoc. 2022;17(4):1028–72. https://doi.org/10.1038/\ns41596-021-00670-7.\nArticle  PubMed  CAS  Google Scholar \n97. Al-Samydai A, Abu Hajleh MN, Al-Sahlawi F, et al. Advancements\nof metallic nanoparticles: a promising frontier in cancer treatment.\nSci Prog. 2024;107(4):00368504241274967. https://\ndoi.org/10.1177/00368504241274967.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n98. Mousa SA, Bharali DJ. Nanotechnology-based detection and\ntargeted therapy in cancer: nano-bio paradigms and applications.\nCancers. 2011;3(3):2888–903. https://doi.org/10.3390/\ncancers3032888.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n99. Castaneda RT, Khurana A, Khan R, et al. Labeling stem cells with\n\nferumoxytol, an FDA-approved iron oxide nanoparticle. J Vis Exp.\n2011;4(57): e3482. https://doi.org/10.3791/3482.\nArticle  CAS  Google Scholar \n100. Kadhum WR, Majeed AA, Saleh RO, et al. Overcoming drug\nresistance with specific nano scales to targeted therapy: focused\non metastatic cancers. Pathol Res Pract. 2024. https://\ndoi.org/10.1016/j.prp.2024.155137.\nArticle  PubMed  Google Scholar \n101. Basoglu H, Goncu B, Akbas F. Magnetic nanoparticle-mediated\ngene therapy to induce Fas apoptosis pathway in breast cancer.\nCancer Gene Ther. 2018;25(5):141–7. https://doi.org/10.1038/\ns41417-018-0017-2.\nArticle  PubMed  CAS  Google Scholar \n102. Meng J, Fan J, Galiana G, et al. LHRH-functionalized\nsuperparamagnetic iron oxide nanoparticles for breast cancer\ntargeting and contrast enhancement in MRI. Mater Sci Eng C.\n2009;29(4):1467–79. https://doi.org/10.1016/j.msec.2008.09.039.\nArticle  CAS  Google Scholar \n103. Legge CJ, Colley HE, Lawson MA, et al. Targeted magnetic\nnanoparticle hyperthermia for the treatment of oral cancer. J Oral\nPathol Med. 2019;48(9):803–9. https://doi.org/10.1111/jop.12921.\n\nArticle  PubMed  CAS  Google Scholar \n104. Ning S, Dai X, Tang W, et al. Cancer cell membrane-coated C-\nTiO2 hollow nanoshells for combined sonodynamic and hypoxia-\nactivated chemotherapy. Acta Biomater. 2022;152:562–74. https://\ndoi.org/10.1016/j.actbio.2022.08.067.\nArticle  PubMed  CAS  Google Scholar \n105. Chen Y, Meng W, Chen M, et al. Biotin-decorated hollow gold\nnanoshells for dual-modal imaging-guided NIR-II photothermal and\nradiosensitizing therapy toward breast cancer. J Mater Chem B.\n2023;11(41):10003–18. https://doi.org/10.1039/D3TB01736B.\nArticle  PubMed  CAS  Google Scholar \n106. Popp MK, Oubou I, Shepherd C, et al. Photothermal therapy using\ngold nanorods and near-infrared light in a murine melanoma model\nincreases survival and decreases tumor volume. J Nanomater.\n2014;2014(1): 450670. https://doi.org/10.1155/2014/450670.\nArticle  CAS  Google Scholar \n107. Lucky SS, Soo KC, Zhang Y. Nanoparticles in photodynamic\ntherapy. Chem Rev. 2015;115(4):1990–2042. https://\ndoi.org/10.1021/cr5004198.\nArticle  PubMed  CAS  Google Scholar \n108. Barenholz YC. Doxil®—The first FDA-approved nano-drug:\n\nLessons learned. J Control Release. 2012;160(2):117–34. https://\ndoi.org/10.1016/j.jconrel.2012.03.020.\nArticle  PubMed  CAS  Google Scholar \n109. Desai N. Nanoparticle albumin-bound paclitaxel (Abraxane®). In:\nAlbumin in medicine: Pathological and clinical applications.\nSpringer; 2016. pp. 101–119. https://\ndoi.org/10.1007/978-981-10-2116-9_6\n110. Shi J, Kantoff PW, Wooster R, et al. Cancer nanomedicine:\nprogress, challenges and opportunities. Nat Rev Cancer.\n2017;17(1):20–37. https://doi.org/10.1038/nrc.2016.108.\nArticle  PubMed  CAS  Google Scholar \n111. Hare JI, Lammers T, Ashford MB, et al. Challenges and strategies\nin anti-cancer nanomedicine development: an industry perspective.\nAdv Drug Deliv Rev. 2017;108:25–38. https://doi.org/10.1016/\nj.addr.2016.04.025.\nArticle  PubMed  CAS  Google Scholar \n112. You J, Zhang R, Xiong C, et al. Effective photothermal\nchemotherapy using doxorubicin-loaded gold nanospheres that\ntarget EphB4 receptors in tumors. Cancer Res. 2012;72(18):4777–\n86. https://doi.org/10.1158/0008-5472.CAN-12-1003.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n\n113. Moorthy H, Govindaraju T. Dendrimer architectonics to treat\ncancer and neurodegenerative diseases with implications in\ntheranostics and personalized medicine. ACS Appl Bio Mater.\n2021;4(2):1115–39. https://doi.org/10.1021/acsabm.0c01319.\nArticle  PubMed  CAS  Google Scholar \n114. Shinde VR, Revi N, Murugappan S, et al. Enhanced permeability\nand retention effect: a key facilitator for solid tumor targeting by\nnanoparticles. Photodiagnosis Photodyn Ther. 2022;39: 102915.\nhttps://doi.org/10.1016/j.pdpdt.2022.102915.\nArticle  PubMed  CAS  Google Scholar \n115. Ejigah V, Owoseni O, Bataille-Backer P, et al. Approaches to\nimprove macromolecule and nanoparticle accumulation in the\ntumor microenvironment by the enhanced permeability and\nretention effect. Polym. 2022;14(13):2601. https://doi.org/10.3390/\npolym14132601.\nArticle  CAS  Google Scholar \n116. Wu J. The enhanced permeability and retention (EPR) effect: the\nsignificance of the concept and methods to enhance its\napplication. J Pers Med. 2021;11(8):771. https://doi.org/10.3390/\njpm11080771.\nArticle  PubMed  PubMed Central  Google Scholar \n117. Huang D, Sun L, Huang L, et al. Nanodrug delivery systems\n\nmodulate tumor vessels to increase the enhanced permeability\nand retention effect. J Pers Med. 2021;11(2):124. https://\ndoi.org/10.3390/jpm11020124.\nArticle  PubMed  PubMed Central  Google Scholar \n118. Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR:\nStrategies to enhance patient responses. Adv Drug Deliv Rev.\n2018;130:17–38. https://doi.org/10.1016/j.addr.2018.07.007.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n119. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid\ntumors. Nature reviews. Clin Oncol. 2010;7(11):653–64. https://\ndoi.org/10.1038/nrclinonc.2010.139.\nArticle  CAS  Google Scholar \n120. Eloy JO, Petrilli R, Chesca DL, et al. Anti-HER2 immunoliposomes\nfor co-delivery of paclitaxel and rapamycin for breast cancer\ntherapy. Eur J Pharm Biopharm. 2017;115:159–67. https://\ndoi.org/10.1016/j.ejpb.2017.02.020.\nArticle  PubMed  CAS  Google Scholar \n121. Lu J, Gao X, Wang S, et al. Advanced strategies to evade the\nmononuclear phagocyte system clearance of nanomaterials.\nInExploration. 2023;3(1):20220045. https://doi.org/10.1002/\nEXP.20220045.\n\nArticle  Google Scholar \n122. Akbari B, Farajnia S, Ahdi Khosroshahi S, et al. Immunotoxins in\ncancer therapy: review and update. Int Rev Immunol.\n2017;36(4):207–19. https://\ndoi.org/10.1080/08830185.2017.1284211.\nArticle  PubMed  CAS  Google Scholar \n123. Mirkasymov AB, Zelepukin IV, Nikitin PI, et al. In vivo blockade of\nmononuclear phagocyte system with solid nanoparticles: Efficiency\nand affecting factors. J Control Release. 2021;330:111–8. https://\ndoi.org/10.1016/j.jconrel.2020.12.004.\nArticle  PubMed  CAS  Google Scholar \n124. Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan\nwith fluorouracil and folinic acid in metastatic pancreatic cancer\nafter previous gemcitabine-based therapy (NAPOLI-1): a global,\nrandomised, open-label, phase 3 trial. The Lancet.\n2016;387(10018):545–57. https://doi.org/10.1016/\nS0140-6736(15)00986-1.\nArticle  CAS  Google Scholar \n125. Peer D, Zhu P, Carman CV, et al. Selective gene silencing in\nactivated leukocytes by targeting siRNAs to the integrin\nlymphocyte function-associated antigen-1. Proc Natl Acad Sci.\n2007;104(10):4095–100. https://doi.org/10.1073/\npnas.0608491104.\n\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n126. Sakamoto JH, van de Ven AL, et al. Enabling individualized\ntherapy through nanotechnology. Pharmacol Res. 2010;62(2):57–\n89. https://doi.org/10.1016/j.phrs.2009.12.011.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n127. Rodríguez F, Caruana P, De la Fuente N, et al. Nano-based\napproved pharmaceuticals for cancer treatment: present and future\nchallenges. Biomolecules. 2022;12(6):784. https://doi.org/10.3390/\nbiom12060784.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n128. Zhang C, Yan L, Wang X, et al. Progress, challenges, and future of\nnanomedicine. Nano Today. 2020;35: 101008. https://\ndoi.org/10.1016/j.nantod.2020.101008.\nArticle  CAS  Google Scholar \n129. Yu Z, Gao L, Chen K, et al. Nanoparticles: a new approach to\nupgrade cancer diagnosis and treatment. Nanoscale Res Lett.\n2021;16(1):88. https://doi.org/10.1186/s11671-021-03489-z.\nArticle  PubMed  PubMed Central  CAS  Google Scholar \n130. Aslam H, Shukrullah S, Naz MY, et al. Current and future\nperspectives of multifunctional magnetic nanoparticles based\ncontrolled drug delivery systems. J Drug Deliv Sci Technol.\n\n2022;67: 102946. https://doi.org/10.1016/j.jddst.2021.102946.\nArticle  CAS  Google Scholar \n131. Khot VM, Salunkhe AB, Pricl S, et al. Nanomedicine-driven\nmolecular targeting, drug delivery, and therapeutic approaches to\ncancer chemoresistance. Drug Discov Today. 2021;26(3):724–39.\nhttps://doi.org/10.1016/j.drudis.2020.12.016.\nArticle  PubMed  CAS  Google Scholar \n132. Gao S, Yang X, Xu J, et al. Nanotechnology for boosting cancer\nimmunotherapy and remodeling tumor microenvironment: the\nhorizons in cancer treatment. ACS Nano. 2021;15(8):12567–603.\nhttps://doi.org/10.1021/acsnano.1c02103.\nArticle  PubMed  CAS  Google Scholar \n133. Fadeel B, Garcia-Bennett AE. Better safe than sorry:\nUnderstanding the toxicological properties of inorganic\nnanoparticles manufactured for biomedical applications. Adv Drug\nDeliv Rev. 2010;62(3):362–74. https://doi.org/10.1016/\nj.addr.2009.11.008.\nArticle  PubMed  CAS  Google Scholar \n134. Ribeiro AR, Leite PE, Falagan-Lotsch P, et al. Challenges on the\ntoxicological predictions of engineered nanoparticles. NanoImpact.\n2017;8:59–72. https://doi.org/10.1016/j.impact.2017.07.006.\n\nArticle  Google Scholar \nDownload references\nAcknowledgements\nNot applicable.\nFunding\nNone.\nAuthor information\nAuthors and Affiliations\n1. School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan\n(Deemed to be University), Bhubaneswar, Odisha, 751003, India\nDinesh Kumar Sharma\nAuthors\n1. Dinesh Kumar Sharma\nView author publications\nSearch author on:PubMed Google Scholar\n\nContributions\nD.K.S. wrote the main manuscript, prepared the figures and table, and\nthen reviewed the entire document.\nCorresponding author\nCorrespondence to Dinesh Kumar Sharma.\nEthics declarations\nConflict of interest\nThe authors declare no competing interests.\nEthical approval and consent to participate\nNot applicable.\nConsent for publication\nThe authors have read and approved the entire manuscript, it has not\nbeen published elsewhere, and it has not been submitted simultaneously\nfor publication elsewhere.\nAdditional information\n\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in\npublished maps and institutional affiliations.\nRights and permissions\nSpringer Nature or its licensor (e.g. a society or other partner) holds\nexclusive rights to this article under a publishing agreement with the\nauthor(s) or other rightsholder(s); author self-archiving of the accepted\nmanuscript version of this article is solely governed by the terms of such\npublishing agreement and applicable law.\nReprints and permissions\nAbout this article\n[image]\nCite this article\nSharma, D.K. Recent advancements in nanoparticles for cancer\ntreatment. Med Oncol 42, 72 (2025). https://doi.org/10.1007/\ns12032-025-02609-4\nDownload citation\n•  Received: 13 December 2024\n\n•  Accepted: 13 January 2025\n•  Published: 10 February 2025\n•  DOI: https://doi.org/10.1007/s12032-025-02609-4\nKeywords\n•  Cancer\n•  Anticancer drugs\n•  Nanoparticles\n•  Drug delivery\n•  Drug targeting\nAccess this article\nLog in via an institution \nSubscribe and save\n Springer+\nfrom €37.37 /Month\n•  Starting from 10 chapters or articles per month\n•  Access and download chapters and articles from more than 300k\nbooks and 2,500 journals\n•  Cancel anytime\n\nView plans \nBuy Now\nBuy article PDF 39,95 €\nPrice includes VAT (Indonesia)\nInstant access to the full article PDF.\nInstitutional subscriptions \nAdvertisement\nSearch\nSearch by keyword or author\n Search\nNavigation\n•  Find a journal\n•  Publish with us\n•  Track your research\nDiscover content\n•  Journals A-Z\n•  Books A-Z\n\nPublish with us\n•  Journal finder\n•  Publish your research\n•  Language editing\n•  Open access publishing\nProducts and services\n•  Our products\n•  Librarians\n•  Societies\n•  Partners and advertisers\nOur brands\n•  Springer\n•  Nature Portfolio\n•  BMC\n•  Palgrave Macmillan\n•  Apress\n•  Discover\n•  Your privacy choices/Manage cookies\n•  Your US state privacy rights\n•  Accessibility statement\n•  Terms and conditions\n•  Privacy policy\n\n•  Help and support\n•  Legal notice\n•  Cancel contracts here\n103.141.47.103\nNot affiliated\n[image]\n© 2025 Springer Nature",
  "api_meta": {
    "id": "10.1007_s12032-025-02609-4",
    "title": "Recent advancements in nanoparticles for cancer treatment",
    "doi": "10.1007/s12032-025-02609-4",
    "source": "crossref"
  }
}